INKT insider trading
NasdaqCM HealthcareMiNK Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About MiNK Therapeutics, Inc.
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Company website: minktherapeutics.com
INKT insider activity at a glance
FilingIQ has scored 112 insider transactions for INKT since Oct 19, 2021. The most recent filing in our index is dated Mar 10, 2026.
Across the full history, 17 open-market purchases
and 7 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on INKT insider trades is 52.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for INKT?
- FilingIQ tracks 112 Form 4 insider transactions for INKT (MiNK Therapeutics, Inc.), covering filings from Oct 19, 2021 onwards. 6 of those were filed in the last 90 days.
- Are INKT insiders net buyers or net sellers?
- Across the full Form 4 history for INKT, 17 transactions (15%) were open-market purchases and 7 (6%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does INKT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is INKT in?
- MiNK Therapeutics, Inc. (INKT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $53.37M.
Methodology & sources
Every INKT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.